AAA
EPRX

Affinity Asset Advisors’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Affinity Asset Advisors’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9M Buy
1,650,000
+60,995
+4% +$421K 0.49% 58
2026
Q1 		$11.5M Buy
1,589,005
+1,289,005
+430% +$10.4M 0.59% 43
2025
Q4 		$2.27M Hold
300,000
– – 0.13% 80
2025
Q3 		$1.77M Buy
+300,000
New +$1.63M 0.15% 78

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Affinity Asset Advisors's EPRX Position: Q2 2026 in Review

Affinity Asset Advisors increased its Eupraxia Pharmaceuticals (EPRX) stake by 3.8% in Q2 2026, buying an estimated $421K and bringing the position to 1,650,000 shares worth $10.9M. The position accounts for 0.49% of the portfolio, ranked #58.

Affinity Asset Advisors first reported a position in EPRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $11.5M in Q1 2026. 68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Affinity Asset Advisors held 1,650,000 shares of Eupraxia Pharmaceuticals worth $10.9M as of Q2 2026.
  • Affinity Asset Advisors bought 60,995 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $421K.
  • Eupraxia Pharmaceuticals made up 0.49% of Affinity Asset Advisors's portfolio in Q2 2026, its #58 holding.
  • Affinity Asset Advisors first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Affinity Asset Advisors's Eupraxia Pharmaceuticals position peaked at $11.5M in Q1 2026.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.